Physician profile
Ferdinand Addo
NPI 1760461388
$663.04
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $563 · 2020: $100.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma Global Development | $95.64 | 2019-2020 | |
| Janssen Scientific Affairs, LLC | $93.90 | 2019 | |
| Pharmacyclics LLC, An Abbvie Company | $91.17 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $72.55 | 2019 | |
| Janssen Biotech, INC. | $65.31 | 2019 | |
| Tesaro, INC. | $43.14 | 2019 | |
| Celgene Corporation | $32.34 | 2019 | |
| Merck Sharp & Dohme LLC | $28.96 | 2019 | |
| Novocure INC. | $27.86 | 2019 | |
| Seagen INC. | $27.58 | 2019 | |
| Exelixis INC. | $21.20 | 2019 | |
| Amgen INC. | $14.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $13.07 | 2020 | |
| Genzyme Corporation | $12.45 | 2019 | |
| Pfizer INC. | $11.66 | 2019 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $11.65 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ferdinand Addo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.